RxDoctor Payments Data

Nimit Desai, MD

Cardiovascular Disease · Geneva, ILNPI 1467866475

Payments from drug & device makers

$4,288in general payments, 2019–2025

Across 19 payments — averaging $225.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$4K
  • Novartis$208
  • Pfizer$125
  • AstraZeneca$125
  • Johnson & Johnson$120
  • Abiomed$43
  • plus $47 from 2 others

What the payments were for

  • Speaking & faculty fees$3,42180%
  • Food & beverage$86720%

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,288 in reported general payments places this provider in the 65th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$226,031
Medicare patients
3,201
Services billed
5,649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban176$265,424
XareltoRivaroxaban160$191,749
EntrestoSacubitril/Valsartan49$59,463
JardianceEmpagliflozin32$45,740
Repatha SureclickEvolocumab29$34,055
Praluent PenAlirocumab41$28,094
BrilintaTicagrelor18$11,258
FarxigaDapagliflozin Propanediol11$10,530
Metoprolol Succinate487$6,474
Rosuvastatin Calcium354$5,169
Atorvastatin Calcium435$4,570
Ezetimibe102$3,071
Diltiazem 24hr Er (Cd)Diltiazem Hcl58$2,448
Amlodipine Besylate337$2,354
Bumetanide39$1,892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$125$265,424176 claims
Johnson & JohnsonXarelto$120$191,749160 claims
NovartisEntresto$208$59,46349 claims
AstraZenecaBrilinta, Farxiga$125$21,78829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Geneva

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →